PSA和MRI前列腺癌筛查会降低死亡率,与乳腺癌筛查相似,检测率和可控风险相当。 PSA and MRI screening for prostate cancer reduces mortality similarly to breast cancer screening, with comparable detection rates and manageable risks.

一项新的研究发现,前列腺癌筛查,加上PSA检测,然后是MRI, 与乳腺癌筛查一样,在降低死亡率和发现重大癌症方面同样有效,在入侵性癌症检测和非侵袭性癌症识别方面也有类似结果。 A new study finds prostate cancer screening with PSA testing followed by MRI is as effective as breast cancer screening in reducing mortality and detecting significant cancers, with similar outcomes in invasive cancer detection and non-aggressive cancer identification. 尽管前列腺检查的假阳性较高,但生物检查率和重大癌症的检测率相当,积极监测可减少治疗风险。 Though false positives were higher for prostate screening, biopsy rates and detection of significant cancers were comparable, and active surveillance reduces overtreatment risks. 研究人员说,如果管理得当,好处大于伤害,敦促更新指导方针,使男女两性都能公平地获得筛查。 Researchers say the benefits outweigh harms when properly managed, urging updated guidelines and equitable access to screening for both genders.